The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert. Calquence (acalabrutinib) and ...
The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 ...
-- FDA Approves Updated Rituxan Prescribing Information to Include Retreatment in RA Patients with an Inadequate Response to TNF Therapies -- South San Francisco, Calif. -- October 17, 2009 -- ...
SOUTH SAN FRANCISCO, Calif. & WESTON, Mass.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today positive data ...
Last night, the Food and Drug Administration announced its approval of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC) for the treatment of CD20-positive chronic ...
RITUXAN SC is a new treatment option for Canadians living with one of the most common forms of leukemia 1 MISSISSAUGA, ON, March 22, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced ...
Two infusions of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly one year, researchers reported on Wednesday. And Rituxan appears to be twice as ...
The blockbuster cancer drug Rituxan may help treat multiple sclerosis, according to the results of a small clinical trial that opens up a broad new approach to understanding and possibly treating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback